Shots:
QIAGEN signed a definitive agreement to acquire Parse Biosciences, expanding QIAGEN’s sample technologies portfolios and digital insights
Under the agreement, QIAGEN will acquire Parse Biosciences for $225M upfront cash plus up to $55M in milestone payments. The deal is expected to close in December 2025, and Parse is projected to add $40M in sales…
Shots:
As life sciences organizations increasingly adopt integrated data, AI, and advanced analytics, CRM platforms are becoming powerful tools to anticipate customer needs, personalize engagements, and measure impact in real-time across multiple channels
In the coming years, CRM will transform into a strategic intelligence hub, empowering teams to make data-driven decisions and helping companies…
Shots:
In this captivating episode of the CXO Talks Podcast, PharmaShots sits down with Josh Wittner, President, North America at Gene By Gene, to explore the company’s evolution and impact in the field of genetic testing
Gene By Gene, a leading commercial genetic testing company, delivers cutting-edge genetic data services spanning a broad range of…
Shots:
Citius Pharmaceuticals celebrates its first-ever FDA approval with Lymphir, a novel therapy for relapsed or refractory cutaneous T-cell lymphoma
In an exclusive conversation, Leonard Mazur, Co-Founder and CEO at Citius Pharmaceuticals, shares insights on Lymphir’s launch strategy and its potential impact on the oncology landscape
Leonard also highlights Mino-Lok, Citius’ innovative…
Digital transformation of the pharmaceutical industry is moving beyond buzzwords to real-world impact. At the Pharmaceutical Automation & Digitalisation Congress AUTOMA+ 2025 (24-25 November, Vösendorf, Austria), pharma leaders, including ZETA GmbH, Takeda and Sapio Sciences, are going to showcase how cutting-edge technologies, from digital twins and predictive analytics to minimal code platforms and AI-driven process…
Shots:
Welcome to the September edition of Know Your Investor, featuring leading investors fuelling healthcare & life sciences
This edition spotlights Cormorant Asset Management, an investment firm focused on biotechnology and healthcare companies
In 2024, Cormorant completed 31 investments ~$3.88B, spanning PIPEs, private financings, IPO, and venture rounds. For the full report, contact us at…
Shots:
Welcome to the August edition of Know Your Investor, featuring leading venture capital firms fuelling innovation in healthcare and life sciences
This edition spotlights Venrock Healthcare Capital Partners, a venture capital fund focused on investments in both publicly and privately held healthcare companies
In 2024, Venrock Healthcare Capital Partners invested approximately $4.56B across six…
Shots:
Welcome to the 2025 edition of Know Your Investor, highlighting top venture capital firms driving healthcare innovation
This edition features Deep Track Capital, a firm dedicated to investing in life sciences companies that are advancing innovations to improve public health
In 2024, Deep Track Capital invested approximately $4.35B across six funding rounds, adding 32…
Shots:
Welcome to the 2025 edition of Know Your Investor, spotlighting leading venture capital firms driving innovation in healthcare.
This edition features Alexandria Venture Investments, a firm committed to supporting disruptive life science companies that aim to improve human health.
In 2024, the firm invested approximately $2.7B across six public and private funding rounds, adding…
PharmaShots is pleased to announce a new strategic data partnership with AlphaSense, marking an important milestone in our mission to elevate the quality, accessibility, and impact of insights across the biopharma and healthcare ecosystem.
This collaboration strengthens our commitment to reimagining intelligence and delivering unmatched industry updates that empower researchers, students, analysts, and biopharma professionals worldwide. By…

